Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial

医学 肿块切除术 乳腺癌 乳房切除术 放射治疗 保乳手术 肿瘤科 内科学 癌症
作者
Douglas W. Arthur,Kathryn A Winter,Henry M. Kuerer,Bruce George Haffty,Laurie W. Cuttino,Dorin A. Todor,Pramila Rani Anne,Penny R. Anderson,Wendy A. Woodward,Beryl L. McCormick,Sally B. Cheston,Walter M. Sahijdak,Daniel J. Canaday,Doris R. Brown,Adam D. Currey,Christine M. Fisher,Reshma Jagsi,Jennifer Moughan,Julia R. White
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:6 (1): 75-75 被引量:155
标识
DOI:10.1001/jamaoncol.2019.4320
摘要

IMPORTANCE: Mastectomy is standard for recurrence of breast cancer after breast conservation therapy with whole breast irradiation. The emergence of partial breast irradiation led to consideration of its application for reirradiation after a second lumpectomy for treatment of recurrence of breast cancer in the ipsilateral breast. OBJECTIVES: To assess the effectiveness and adverse effects of partial breast reirradiation after a second lumpectomy and whether the treatment is an acceptable alternative to mastectomy. DESIGN, SETTING, AND PARTICIPANTS: The NRG Oncology/Radiation Therapy Oncology Group 1014 trial is a phase 2, single-arm, prospective clinical trial of 3-dimensional, conformal, external beam partial breast reirradiation after a second lumpectomy for recurrence of breast cancer in the ipsilateral breast after previous whole breast irradiation. The study opened on June 4, 2010, and closed June 18, 2013. Median follow-up was 5.5 years. This analysis used all data received at NRG Oncology through November 18, 2018. Eligible patients experienced a recurrence of breast tumor that was less than 3 cm and unifocal in the ipsilateral breast more than 1 year after breast-conserving therapy with whole breast irradiation and who had undergone excision with negative margins. INTERVENTIONS: Adjuvant partial breast reirradiation, 1.5 Gy twice daily for 30 treatments during 15 days (45 Gy), using a 3-dimensional conformal technique. MAIN OUTCOMES AND MEASURES: The main outcomes of the present study were the predefined secondary study objectives of recurrence of breast cancer in the ipsilateral breast, late adverse events (>1 year after treatment), mastectomy incidence, distant metastasis-free survival, overall survival, and circulating tumor cell incidence. RESULTS: A total of 65 women were enrolled, with 58 evaluable for analysis (mean [SD] age, 65.12 [9.95] years; 48 [83%] white). Of the recurrences of breast cancer in the ipsilateral breast, 23 (40%) were noninvasive and 35 (60%) were invasive. In all 58 patients, 53 (91%) had tumors 2 cm or smaller. All tumors were clinically node negative. A total of 44 patients (76%) tested positive for estrogen receptor, 33 (57%) for progesterone receptor, and 10 (17%) for ERBB2 (formerly HER2 or HER2/neu) overexpression. Four patients had breast cancer recurrence, with a 5-year cumulative incidence of 5% (95% CI, 1%-13%). Seven patients underwent ipsilateral mastectomies for a 5-year cumulative incidence of 10% (95% CI, 4%-20%). Both distant metastasis-free survival and overall survival rates were 95% (95% CI, 85%-98%). Four patients (7%) had grade 3 and none had grade 4 or higher late treatment adverse events. CONCLUSIONS AND RELEVANCE: For patients experiencing recurrence of breast cancer in the ipsilateral breast after lumpectomy and whole breast irradiation, a second breast conservation was achievable in 90%, with a low risk of re-recurrence of cancer in the ipsilateral breast using adjuvant partial breast reirradiation. This finding suggests that this treatment approach is an effective alternative to mastectomy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
一米七的小柯基完成签到,获得积分10
2秒前
小慧慧完成签到 ,获得积分10
2秒前
2秒前
科研通AI6.2的应助被喷火龙采纳,获得10
2秒前
2秒前
clevenx发布了新的文献求助10
3秒前
4秒前
无题完成签到,获得积分10
4秒前
6秒前
6秒前
7秒前
温夜天完成签到,获得积分10
7秒前
7秒前
星辰大海的应助被皮夏寒采纳,获得10
7秒前
7秒前
8秒前
开朗含海完成签到,获得积分10
8秒前
9秒前
10秒前
wanci的应助被dandelion采纳,获得10
10秒前
yayaya完成签到 ,获得积分10
10秒前
韦智杰发布了新的文献求助10
11秒前
11秒前
玉玉玉米发布了新的文献求助10
11秒前
开朗含海发布了新的文献求助10
12秒前
风语村发布了新的文献求助10
12秒前
小姜完成签到 ,获得积分10
12秒前
taipingyang发布了新的文献求助10
13秒前
YangyangShi完成签到 ,获得积分10
13秒前
传奇3的应助被科研通管家采纳,获得10
14秒前
clevenx完成签到,获得积分10
14秒前
李爱国的应助被科研通管家采纳,获得10
14秒前
赘婿的应助被科研通管家采纳,获得10
14秒前
Owen的应助被科研通管家采纳,获得10
14秒前
小蘑菇的应助被科研通管家采纳,获得10
14秒前
君为臣纲的应助被科研通管家采纳,获得10
14秒前
无花果的应助被科研通管家采纳,获得10
14秒前
无花果的应助被科研通管家采纳,获得10
14秒前
小马甲的应助被科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194107
求助须知:如何正确求助?哪些是违规求助? 9580062
关于积分的说明 21869017
捐赠科研通 7793713
什么是DOI,文献DOI怎么找? 3437523
关于科研通互助平台的介绍 2560962
邀请新用户注册赠送积分活动 2484264